# De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer

> **NCT06446557** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University Hospital, Rouen** · enrollment: 408 (estimated)

## Conditions studied

- Metastatic Colon Cancer

## Interventions

- **DRUG:** treatment adaptation guided by ctDNA variation
- **DRUG:** standard management

## Key facts

- **NCT ID:** NCT06446557
- **Lead sponsor:** University Hospital, Rouen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2032-06-01
- **Final completion:** 2032-06-01
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06446557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06446557, "De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06446557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*